Galderma stock: Shareholders approve dividend and board refresh

Galderma shareholders approved all proposals at the company's Annual General Meeting in Zug on April 22, 2026, according to a Galderma press release. The resolutions covered a gross dividend of CHF 0.35 per dividend-bearing share, board elections and the approval of the company's 2025 reporting package.

Dividend approval supports shareholder returns

The dividend is to be distributed from reserves from capital contributions. Galderma said the payment structure falls under the applicable Swiss tax rules and noted that the distribution can be free from Swiss withholding tax under the stated conditions.

For investors, the resolution confirms a direct shareholder return while leaving the company's broader operating strategy outside the scope of the AGM decision. The approved payout is therefore a capital-allocation signal rather than a change to Galderma's dermatology portfolio or financial outlook.

Board gains new L'Oréal representatives

Harry Kirsch was elected as an independent board member. Samuel du Retail and Delphine Viguier-Hovasse, both representatives of L'Oréal, joined as non-independent members. Thomas Ebeling, Daniel Browne, Maria Teresa Hilado, Karen Lee Ling, Roberto Marques, Sherilyn McCoy and Flemming Ornskov were re-elected.

The result combines continuity in the boardroom with additional representation linked to L'Oréal. That mix matters for shareholders because board composition shapes oversight, governance and the handling of long-term strategic priorities.

Reporting approvals add continuity

Shareholders also approved Galderma's 2025 Annual Financial Statements, Non-Financial Report and Compensation Report. The company said detailed voting results and the official minutes would be published on its investor-relations website within two weeks of the meeting.

Galderma stock traded at 207.00 euros on Lang & Schwarz at 12:20 CET on Wednesday, November 11, 2026. The quote provides the current market reference as the company continues to trade on the governance and shareholder-return decisions approved in April.

Swiss equities continue to trade against the broader backdrop of the SMI market.

For further company-specific developments, see More news and analyses on Galderma stock.